Apoptosis and Cancer Therapy: From Cutting-Edge Science to Novel Therapeutic Concepts
http://www.100md.com
《新英格兰医药杂志》
Among the recent offering of new books regarding therapy that targets the apoptotic process, this two-volume work is distinctive because of its wide scope and depth. The contributors are all leading experts in their fields in Europe, North America, Australia, and Japan.
The chapters of the first volume have been grouped into 10 sections: "Death Receptor," "Mitochondria," "Effector Systems," "Bcl-2 Family," "IAPs ," "Survival Pathways," "Oncogenes/Tumor Suppressor Genes," "Modulators," "Lysosomes and Nonapoptotic Pathways," and "Phagocytosis/Clearance." This volume covers almost all stages of apoptotic cell death, starting from the initiation of apoptosis and progressing to its terminal phase. The second volume consists of four sections: "Model Systems," "Molecular Diagnosis," "Cellular Stress, DNA Damage, and Repair," and "Molecular Targets and Therapeutics."
The 11 chapters in the final section of volume 2 cover the latest advances in the development of innovative apoptosis-targeted therapy for cancer; they are of paramount interest and will be of value to anyone interested in the field of oncology. In particular, chapter 33, "Therapeutic Modulation of Apoptosis in Cancer Therapy," a concise review by the editors of the book, Klaus-Michael Debatin and Simone Fulda, gives an excellent picture of strategies that target aberrant signaling pathways of apoptosis in tumor cells. Chapter 34 is a useful discussion of caspase- and IAP-based therapeutics. The small-molecule caspase activators are still in preclinical trials, but antisense oligonucleotides have recently entered phase 1 clinical trials. The authors of the chapter, Ute Fischer and Klaus Schulze-Osthoff, state, "Given that the field of apoptosis research is not more than 15 years old, the fact that first-generation therapeutics are now in human clinical trials is already a tremendous success." I would completely agree with this statement.
Succeeding chapters cover therapeutic strategies for targeting wild-type or mutant p53, IAPs, Hsp90, and the PI3K–AKT–mTOR pathway. The book emphasizes direct inducers of apoptosis and modulators of the apoptotic threshold that reinforce the response to radiation. In a nutshell, this excellent book on research in cell death is on the forefront of modern molecular oncology.
Alex Philchenkov, M.D., Ph.D.
R.E. Kavetsky Institute of Experimental Pathology,
Oncology, and Radiobiology
Kiev 03022, Ukraine
a_philch@onconet.kiev.ua(Edited by Klaus-Michael D)
The chapters of the first volume have been grouped into 10 sections: "Death Receptor," "Mitochondria," "Effector Systems," "Bcl-2 Family," "IAPs ," "Survival Pathways," "Oncogenes/Tumor Suppressor Genes," "Modulators," "Lysosomes and Nonapoptotic Pathways," and "Phagocytosis/Clearance." This volume covers almost all stages of apoptotic cell death, starting from the initiation of apoptosis and progressing to its terminal phase. The second volume consists of four sections: "Model Systems," "Molecular Diagnosis," "Cellular Stress, DNA Damage, and Repair," and "Molecular Targets and Therapeutics."
The 11 chapters in the final section of volume 2 cover the latest advances in the development of innovative apoptosis-targeted therapy for cancer; they are of paramount interest and will be of value to anyone interested in the field of oncology. In particular, chapter 33, "Therapeutic Modulation of Apoptosis in Cancer Therapy," a concise review by the editors of the book, Klaus-Michael Debatin and Simone Fulda, gives an excellent picture of strategies that target aberrant signaling pathways of apoptosis in tumor cells. Chapter 34 is a useful discussion of caspase- and IAP-based therapeutics. The small-molecule caspase activators are still in preclinical trials, but antisense oligonucleotides have recently entered phase 1 clinical trials. The authors of the chapter, Ute Fischer and Klaus Schulze-Osthoff, state, "Given that the field of apoptosis research is not more than 15 years old, the fact that first-generation therapeutics are now in human clinical trials is already a tremendous success." I would completely agree with this statement.
Succeeding chapters cover therapeutic strategies for targeting wild-type or mutant p53, IAPs, Hsp90, and the PI3K–AKT–mTOR pathway. The book emphasizes direct inducers of apoptosis and modulators of the apoptotic threshold that reinforce the response to radiation. In a nutshell, this excellent book on research in cell death is on the forefront of modern molecular oncology.
Alex Philchenkov, M.D., Ph.D.
R.E. Kavetsky Institute of Experimental Pathology,
Oncology, and Radiobiology
Kiev 03022, Ukraine
a_philch@onconet.kiev.ua(Edited by Klaus-Michael D)